Portal de investigación
Contemporary pharmacological management of patients after hip fracture: a population-based cohort of over 120,000 patients in Spain
Autores de FISABIO
Autores ajenos a FISABIO
- Espallargues, M
- García, N
- Gorostiza, I
- Gorricho, J
- Librero, J
- Millán, E
- Modroño, G
- Parraza, N
Grupos de Investigación
Abstract
Treatment with antiosteoporotics is recommended after a hip fracture to reduce the risk of a new fracture or death. In our study, we found a slight increase in treatment rates over time, but an important treatment gap in the contemporary secondary prevention of hip fracture is still present.IntroductionThe pharmacological management of patients after hip fracture is likely to have changed due to the availability of denosumab during the last decade, but the extent of its use and potential improvement in treatment rates in routine clinical practice is largely unknown.MethodsWe constructed a population-based retrospective cohort of all patients aged 65 years + , discharged alive following hip fracture hospitalization (Jan 2008 to Dec 2021) in several regions of Spain, accounting for one third of the country's population. The proportion of patients prescribed any antiosteoporotic (AO) medication and specific classes in the first 90 days after discharge was evaluated. Temporal trends of treatment prescription per month were plotted. All analyses were performed also by age, sex, and region.ResultsIn a cohort of over 120,000 patients, we found an important treatment gap in the secondary prevention of hip fracture (78% of patients untreated). Bisphosphonates and denosumab accounted for 60% and 20% of the AO prescriptions, respectively. Treatment gaps were most pronounced among patients aged 85 and over, and males: 26% of patients aged <= 84 were treated, in contrast to 18% of those aged 85 + . The proportion of females treated nearly doubled that of males (24% vs 14%). Differences by region were observed. Regarding time trends, despite finding an increase over time, prescription rates remained highly suboptimal. By drug class, treatment with bisphosphonates dropped, whereas denosumab treatment rose along the study period. Concerning management by sex, the Mediterranean regions showed a persistent gap over time, whereas in the Northern regions, the gap was gradually reduced. Treatment patterns by age groups were consistent over time.ConclusionsOur study offers evidence to identify current gaps of care in secondary prevention of hip fracture and implement adequate strategies to reduce recurrent fractures in this frail population.
Datos de la publicación
- ISSN/ISSNe:
- 0937-941X, 1433-2965
- Tipo:
- Article
- Páginas:
- -
- PubMed:
- 40650742
OSTEOPOROSIS INTERNATIONAL SPRINGER LONDON LTD
Documentos
- No hay documentos
Filiaciones
Keywords
- Bisphosphonates; Denosumab; Drug use; Health service research; Hip fracture; Osteoporosis
Financiación
Ayudas competitivas y Estudios Clínicos asociados
TRATAMIENTO AL ALTA, ADHERENCIA Y RESULTADOS CLÍNICOS TRAS LA FRACTURA DE CADERA. COHORTE POBLACIONAL CON HASTA 5 AÑOS DE SEGUIMIENTO EN EL SISTEMA NACIONAL DE SALUD (estudio PREV2FO)
Investigador Principal: GABRIEL SANFELIX GIMENO
PI14/00993 . INSTITUTO CARLOS III . 2015
Red de Investigación en Servicios de Salud en Enfermedades Crónicas-REDISSEC
Investigador Principal: ISABEL HURTADO NAVARRO
RD16/0001/0011 . INSTITUTO CARLOS III . 2017
Tratamiento al alta, adherencia y resultados clínicos tras fractura de cadera. Cohorte poblacional con hasta 10 años de seguimiento en el Sistema Nacional de Salud (Estudio PREV2FO2).
Investigador Principal: GABRIEL SANFELIX GIMENO
PI18/01675 . INSTITUTO CARLOS III . 2019
Red de Investigación en Cronicidad, Atención Primaria y Promoción de la Salud (RICAPPS)
Investigador Principal: ISABEL HURTADO NAVARRO
RD21/0016/0006 . INSTITUTO CARLOS III . 2022